In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of CorMedix Inc (NASDAQ: CRMD) was $12.73 for the day, up 1.60% from the previous closing price of $12.53. In other words, the price has increased by $1.60 from its previous closing price. On the day, 2.17 million shares were traded. CRMD stock price reached its highest trading level at $12.82 during the session, while it also had its lowest trading level at $12.36.
Ratios:
Our analysis of CRMD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.48. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.94. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 18 ’25 when Todisco Joseph sold 30,000 shares for $12.00 per share. The transaction valued at 360,000 led to the insider holds 509,496 shares of the business.
Joseph Todisco bought 30,000 shares of CRMD for $359,149 on Dec 18 ’25. On Dec 09 ’25, another insider, Dillione Janet, who serves as the Director of the company, sold 34,000 shares for $12.00 each. As a result, the insider received 408,000 and left with 48,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 1002984576 and an Enterprise Value of 1096188672. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.20, and their Forward P/E ratio for the next fiscal year is 5.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.68 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 5.115 whereas that against EBITDA is 10.131.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.38, which has changed by 0.5469136 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 15.20%, while the 200-Day Moving Average is calculated to be 13.12%.
Shares Statistics:
CRMD traded an average of 2.72M shares per day over the past three months and 2405000 shares per day over the past ten days. A total of 78.35M shares are outstanding, with a floating share count of 69.21M. Insiders hold about 12.15% of the company’s shares, while institutions hold 56.57% stake in the company. Shares short for CRMD as of 1765756800 were 16875402 with a Short Ratio of 6.20, compared to 1763078400 on 17445325. Therefore, it implies a Short% of Shares Outstanding of 16875402 and a Short% of Float of 21.63.
Earnings Estimates
. The current rating of CorMedix Inc (CRMD) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.72, with high estimates of $0.72 and low estimates of $0.72.
Analysts are recommending an EPS of between $2.85 and $2.42 for the fiscal current year, implying an average EPS of $2.63. EPS for the following year is $2.5, with 2.0 analysts recommending between $2.53 and $2.47.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $135.16M to a low estimate of $120M. As of. The current estimate, CorMedix Inc’s year-ago sales were $31.21MFor the next quarter, 7 analysts are estimating revenue of $127.41M. There is a high estimate of $127.41M for the next quarter, whereas the lowest estimate is $127.41M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $318.25M, while the lowest revenue estimate was $303.09M, resulting in an average revenue estimate of $310.62M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $437.27M in the next fiscal year. The high estimate is $503M and the low estimate is $298.1M.
